bpc-157 effects on brain 10 questions to ask your doctor about peptides BPC-157: Nervous System, Gut Health,

Youre working rotating shifts that wreck your sleep and spike your cortisol

Summary: Long-term calorie restriction doesnt appear to directly impact IGF-1 levels in humans, although it may make it less active

Side Effects & Safety AOD-9604 has a favorable safety profile supported by clinical trial data: FDA GRAS status: The compound received GRAS status as a food ingredient, reflecting some regulatory safety evaluation, though this is not equivalent to drug safety approval Clinical trial tolerability: Phase I and Phase II clinical trials conducted by Metabolic Pharmaceuticals generally found AOD-9604 well-tolerated at studied doses Injection site reactions: Minor discomfort with subcutaneous administration Headache and nausea: Reported in some clinical trial subjects No significant metabolic effects: Blood glucose, insulin, HbA1c, and IGF-1 were not significantly altered in clinical studies, which distinguishes it favorably from full GH Long-term safety data for subcutaneous use in the research community context (typically higher and more frequent dosing than clinical trials) is limited

More research is needed to know if intermittent fasting is a reliable way to lower IGF-1

As of April 2026, no FDA guidance formally distinguishing PDA from BPC-157 has been issued